The recall of a significant number of Impella Blood Pumps due to serious health risks, including death, is likely to have a negative impact on Johnson & Johnson's stock in the short term. The high number of reported injuries and deaths, along with the recall of a substantial number of devices, could lead to reputational damage, potential legal liabilities, and financial costs associated with the recall and correction process. Although the recall is described as a correction rather than a product removal, the severity of the issue and its potential implications for patient safety are likely to concern investors and could negatively affect investor sentiment.